BIOGEN INC. Increase (Decrease) in Due from Related Parties
BIOGEN INC. (BIIB) reported Increase (Decrease) in Due from Related Parties of -$37.60 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-04-25.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDueFromRelatedParties · last filed 2023-04-25
- BIOGEN INC. increase (decrease) in due from related parties for the quarter ending 2023-03-31 was -$37.60M.
- BIOGEN INC. increase (decrease) in due from related parties for the quarter ending 2022-09-30 was -$20.60M.
- BIOGEN INC. increase (decrease) in due from related parties for the quarter ending 2022-06-30 was $46.50M, a 11.43% decline year-over-year.
- BIOGEN INC. increase (decrease) in due from related parties for the quarter ending 2022-03-31 was -$22.90M.
| Period end | Increase (Decrease) in Due from Related Parties 3 month | Increase (Decrease) in Due from Related Parties 6 month | Increase (Decrease) in Due from Related Parties 9 month |
|---|---|---|---|
| 2023-03-31 | -$37.60M 10-Q · filed 2023-04-25 | ||
| 2022-09-30 | -$20.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25 | $25.90M derived: sum of 2 quarters · filed 2022-10-25 | $3.00M 10-Q · filed 2022-10-25 |
| 2022-06-30 | $46.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-20 | $23.60M 10-Q · filed 2022-07-20 | |
| 2022-03-31 | -$22.90M 10-Q · filed 2023-04-25 | ||
| 2021-09-30 | -$22.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25 | $30.30M derived: sum of 2 quarters · filed 2022-10-25 | -$13.50M 10-Q · filed 2022-10-25 |
| 2021-06-30 | $52.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-20 | $8.70M 10-Q · filed 2022-07-20 | |
| 2021-03-31 | -$43.80M 10-Q · filed 2022-05-03 | ||
| 2020-09-30 | $86.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-20 | $15.60M derived: sum of 2 quarters · filed 2021-10-20 | -$63.00M 10-Q · filed 2021-10-20 |
| 2020-06-30 | -$70.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-22 | -$149.10M 10-Q · filed 2021-07-22 | |
| 2020-03-31 | -$78.60M 10-Q · filed 2021-04-22 | ||
| 2019-09-30 | $24.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-21 | $55.40M derived: sum of 2 quarters · filed 2020-10-21 | $55.40M 10-Q · filed 2020-10-21 |
| 2019-06-30 | $30.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-22 | $30.60M 10-Q · filed 2020-07-22 | |
| 2019-03-31 | $0.00 10-Q · filed 2020-04-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |